CINCINNATI--(BUSINESS WIRE)--Aug. 30, 2018--
Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced that Chief Executive Officer, Stephen Hoffman, M.D.,
Ph.D., will present at the 20th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC,
on Thursday, September 6, 2018 at 10:00 a.m. Eastern Time in New York,
NY. Dr. Hoffman will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB-9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information, please
visit www.aerpio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005087/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
Aerpio
Pharmaceuticals, Inc.
Michael Rogers
Chief Financial
Officer
mrogers@aerpio.com
or
Burns
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Media:
Robert
Flamm, Ph.D.
rflamm@burnsmc.com
or
Investors:
Ami
Bavishi
abavishi@burnsmc.com
